# A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

> **NCT07459543** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 30 (estimated)

## Conditions studied

- Untreated Melanoma
- Unresectable Melanoma
- Metastatic Melanoma

## Interventions

- **DRUG:** Nivolumab + Relatlimab

## Key facts

- **NCT ID:** NCT07459543
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-15
- **Primary completion:** 2029-05-26
- **Final completion:** 2029-05-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07459543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07459543, "A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT07459543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*